肾葡萄糖重吸收抑制剂的研发：2型糖尿病药物治疗的新机制 - Suppr

Suppr

超能文献

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

作者信息

Washburn William N

机构信息

Metabolic Diseases Chemistry, Research and Development, Bristol-Myers Squibb Co, Princeton, New Jersey 08543, USA.

出版信息

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019.

DOI:10.1021/jm8013019

PMID:19243175

Abstract

摘要

相似文献

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.肾葡萄糖重吸收抑制剂的研发：2型糖尿病药物治疗的新机制

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.钠-葡萄糖协同转运蛋白 2 抑制剂作为抗糖尿病药物的发展历程。

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828.

C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.4'-位取代的 C-芳基葡萄糖苷作为强效和选择性的肾钠依赖性葡萄糖共转运蛋白 2（SGLT2）抑制剂，用于治疗 2 型糖尿病。

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4465-70. doi: 10.1016/j.bmcl.2011.06.032. Epub 2011 Jun 16.

Renal glucose reabsorption inhibitors to treat diabetes.用于治疗糖尿病的肾葡萄糖重吸收抑制剂。

Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4.

Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.构象受限的螺环 C-芳基葡糖苷作为强效且选择性的肾钠依赖性葡萄糖协同转运蛋白 2（SGLT2）抑制剂。

ChemMedChem. 2010 Jun 7;5(6):827-31. doi: 10.1002/cmdc.201000051.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.依帕列净和其他钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在 2 型糖尿病治疗中的作用：临床前和临床数据。

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4.

BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus.BI-10773，一种用于潜在口服治疗2型糖尿病的钠-葡萄糖协同转运蛋白2抑制剂。

Curr Opin Investig Drugs. 2010 Oct;11(10):1182-90.

Empagliflozin (Jardiance) for diabetes.恩格列净（欧唐静）用于治疗糖尿病。

Med Lett Drugs Ther. 2014 Oct 13;56(1453):99-100.

Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.试验观察：SGLT2抑制剂在2型糖尿病治疗中展现出前景。

Nat Rev Drug Discov. 2010 Mar;9(3):182. doi: 10.1038/nrd3127.

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂：治疗 2 型糖尿病的新兴治疗类别。

J Clin Pharmacol. 2012 Apr;52(4):457-63. doi: 10.1177/0091270011400604. Epub 2011 May 4.

引用本文的文献

SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis.SGLT2 抑制剂恩格列净通过抑制铁死亡促进糖尿病小鼠后肢缺血的血管再生。

Acta Pharmacol Sin. 2023 Jun;44(6):1161-1174. doi: 10.1038/s41401-022-01031-0. Epub 2022 Dec 12.

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.钠-葡萄糖共转运蛋白抑制剂作为抗糖尿病药物：当前的发展和未来的展望。

J Med Chem. 2022 Aug 25;65(16):10848-10881. doi: 10.1021/acs.jmedchem.2c00867. Epub 2022 Aug 4.

Phosphonic acid mediated practical dehalogenation and benzylation with benzyl halides.膦酸介导的实用脱卤反应及与卤化苄的苄基化反应。

RSC Adv. 2019 Jul 18;9(39):22343-22347. doi: 10.1039/c9ra04770k. eCollection 2019 Jul 17.

Newly synthesised oxime and lactone derivatives from dipterocarpol as anti-diabetic inhibitors: experimental bioassay-based evidence and theoretical computation-based prediction.从龙脑香二萜醇合成的新型肟和内酯衍生物作为抗糖尿病抑制剂：基于实验生物测定的证据和基于理论计算的预测

RSC Adv. 2021 Nov 4;11(57):35765-35782. doi: 10.1039/d1ra04461c.

Isolation, semi-synthesis, docking-based prediction, and bioassay-based activity of iridoids: new catalpol derivatives as glucosidase inhibitors.环烯醚萜类化合物的分离、半合成、基于对接的预测及基于生物测定的活性：新的梓醇衍生物作为葡萄糖苷酶抑制剂

RSC Adv. 2021 Mar 23;11(20):11959-11975. doi: 10.1039/d1ra00441g.

Styracifoline from the Vietnamese Plant : A Potential Inhibitor of Diabetes-Related and Thrombosis-Based Proteins.来自越南植物的苏合香碱：一种糖尿病相关和血栓形成相关蛋白的潜在抑制剂。

ACS Omega. 2021 Sep 1;6(36):23211-23221. doi: 10.1021/acsomega.1c02840. eCollection 2021 Sep 14.

On the Inhibitability of Natural Products Isolated from towards Tyrosine Phosphatase 1B (PTP1B) and α-Glucosidase (3W37): An In Vitro and In Silico Study.从天然产物中分离得到的对酪氨酸磷酸酶 1B（PTP1B）和α-葡萄糖苷酶（3W37）的抑制作用的不可抑制性：体外和计算研究。

Molecules. 2021 Jun 17;26(12):3691. doi: 10.3390/molecules26123691.

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.评估瑞格列净恩格列净酯（GSK189075）与最大日剂量 2000mg 二甲双胍联合使用的安全性和耐受性。

BMC Pharmacol Toxicol. 2021 Jun 13;22(1):34. doi: 10.1186/s40360-021-00502-0.

Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation.通过分子对接和动力学模拟开发新型结构的钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂。

J Mol Model. 2019 Jun 1;25(6):175. doi: 10.1007/s00894-019-4067-7.

Structural biology workflow for the expression and characterization of functional human sodium glucose transporter type 1 in Pichia pastoris.毕赤酵母中功能性人源葡萄糖转运蛋白 1 的表达和功能表征的结构生物学工作流程。

Sci Rep. 2019 Feb 4;9(1):1203. doi: 10.1038/s41598-018-37445-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验